Recarbrio

Adult Dosing .

Dosage forms:  INJ

Special Note

[strength clarification]

Info: doses expressed as total imipenem + cilastatin + relebactam amount; 1.25 g imipenem/cilastatin/relebactam contains 0.5 g imipenem + 0.5 g cilastatin + 0.25 g relebactam

pneumonia, hospital-acquired or ventilator-associated

[1.25 g IV q6h x7 days]

Info: may extend duration based on clinical response; refer to IDSA guidelines

intra-abdominal infections, complicated

[1.25 g IV q6h x4-14 days]

Info: for patients with limited or no alternative tx options; duration varies with infection type, pathogen susceptibility

UTI, complicated

[1.25 g IV q6h x4-14 days]

Info: for patients with limited or no alternative tx options; duration varies with infection type, pathogen susceptibility

renal dosing

[see below]

CrCl 60-89: 1 g q6h; CrCl 30-59: 0.75 g q6h; CrCl 15-29: 0.5 g q6h; CrCl <15: avoid unless HD within 48h

HD: 0.5 g q6h, on dialysis days administer after dialysis; consider supplement if next maintenance dose not due right after dialysis; PD: not defined

hepatic dosing

[no adjustment]

Peds Dosing .

Dosage forms:  INJ

Special Note

[strength clarification]

Info: doses expressed as total imipenem + cilastatin + relebactam amount; 1.25 g imipenem/cilastatin/relebactam contains 0.5 g imipenem + 0.5 g cilastatin + 0.25 g relebactam

pneumonia, hospital-acquired or ventilator-associated

[37 wk gestation and older, <3 mo, >2 kg]

Dose: 112.5 mg/kg/day IV divided q8h x4-14 days

[3 mo and older, <30 kg]

Dose: 150 mg/kg/day IV divided q6h x4-14 days

[3 mo and older, >30 kg]

Dose: 1.25 g IV q6h x4-14 days

intra-abdominal infections, complicated

[37 wk gestation and older, <3 mo, >2 kg]

Dose: 112.5 mg/kg/day IV divided q8h x4-14 days; Info: for patients with limited or no alternative tx options; duration varies with infection type, pathogen susceptibility

[3 mo and older, <30 kg]

Dose: 150 mg/kg/day IV divided q6h x4-14 days; Info: for patients with limited or no alternative tx options; duration varies with infection type, pathogen susceptibility

[3 mo and older, >30 kg]

Dose: 1.25 g IV q6h x4-14 days; Info: for patients with limited or no alternative tx options; duration varies with infection type, pathogen susceptibility

UTI, complicated

[37 wk gestation and older, <3 mo, >2 kg]

Dose: 112.5 mg/kg/day IV divided q8h x4-14 days; Info: for patients with limited or no alternative tx options; duration varies with infection type, pathogen susceptibility

[3 mo and older, <30 kg]

Dose: 150 mg/kg/day IV divided q6h x4-14 days; Info: for patients with limited or no alternative tx options; duration varies with infection type, pathogen susceptibility

[3 mo and older, >30 kg]

Dose: 1.25 g IV q6h x4-14 days; Info: for patients with limited or no alternative tx options; duration varies with infection type, pathogen susceptibility

renal dosing

[<30 kg]

renal impairment: avoid use

HD/PD: avoid use

[>30 kg]

CrCl 60-89: 1 g q6h; CrCl 30-59: 0.75 g q6h; CrCl 15-29: 0.5 g q6h; CrCl <15: avoid unless HD within 48h

HD: 0.5 g q6h, on dialysis days administer after dialysis; consider supplement if next maintenance dose not due right after dialysis; PD: not defined

hepatic dosing

[no adjustment]